News | February 16, 2024
Glenmark Pharma posts Q3 FY24 net loss of Rs. 331 Cr
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Launches collaborative centre for translational research in head and neck cancer
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
